New Genialis RNA Biomarker Accurately Predicts KRAS Outcomes in Lung Cancer Patients
Genialis , the RNA-biomarker company, today presented a poster on a new AI/ML classifier, Genialis™ krasID, that accurately predicts clinical benefit in a real-world cohort of patients who received sotorasib, a KRAS inhibitor currently approved for KRAS G12C non-small cell lung cancers.
- Genialis , the RNA-biomarker company, today presented a poster on a new AI/ML classifier, Genialis™ krasID, that accurately predicts clinical benefit in a real-world cohort of patients who received sotorasib, a KRAS inhibitor currently approved for KRAS G12C non-small cell lung cancers.
- Genialis krasID analyzes foundational aspects of KRAS biology using RNA-sequencing and a machine learning algorithm comprising numerous biologic signatures.
- Taken together, these early results demonstrate that the Genialis krasID classifier can predict response and stratify durable benefit in experimental and clinical settings.
- Last week, Genialis announced the addition of two new partners as it assembles the world’s most ethnographically diverse cancer data sets .